Who Paid My Doc
Fernando Fuentes
Critical Care Medicine Reno, NV Medical Doctor
NPI 1952669640 CMS profile 1330212
1500 E 2Nd St Ste 302, Ste 302, Reno, NV 89502
General payments
$4,131
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Fernando Fuentes of Reno, NV is reported in the CMS Open Payments database as having received $4,131 across 42 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 83rd percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,930 | 19 | |
| 2024 | General | $236 | 5 | |
| 2023 | General | $1,790 | 15 | |
| 2022 | General | $14 | 1 | |
| 2019 | General | $161 | 2 |
Beside peers
- Fernando Fuentes
- Critical Care Medicine median
- Middle half of Critical Care Medicine
- National median
In program year 2025, general payments to Fernando Fuentes were reported at $1,930. Among 2,664 Critical Care Medicine profiles paid that year, the median was $189 and the middle half received between $59 and $844.
Show as a table
| Year | Fernando Fuentes | Critical Care Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $161 | $149 | $51–$535 | $163 |
| 2020 | $0 | $110 | $30–$325 | $114 |
| 2021 | $0 | $125 | $34–$403 | $132 |
| 2022 | $14 | $157 | $49–$582 | $149 |
| 2023 | $1,790 | $162 | $56–$621 | $160 |
| 2024 | $236 | $168 | $53–$634 | $164 |
| 2025 | $1,930 | $189 | $59–$844 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 7 drugsPart D claims
127
Drug cost
$52,769
Branded share of claims
100%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Spiriva Respimat Tiotropium Bromide | Brand | 24 | $14,971 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 11 | $14,357 | |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | Brand | 23 | $11,430 | |
| Dulera Mometasone/Formoterol | Brand | 11 | $4,711 | |
| Symbicort Budesonide/Formoterol Fumarate | Brand | 17 | $3,862 | |
| Breyna Budesonide/Formoterol Fumarate | Brand | 13 | $2,374 | |
| Albuterol Sulfate Hfa Albuterol Sulfate | Brand | 28 | $1,064 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 18 billing codesPaid by Medicare
$13,006
Medicare patients
112
Services billed
160
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| COPD | 70% | |
| High blood pressure | 63% | |
| Arthritis | 53% | |
| Ischemic heart disease | 46% | |
| Depression | 31% | |
| Chronic kidney disease | 27% | |
| Diabetes | 24% | |
| Heart failure | 23% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
2 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| TYVASO |
|
$148 | — | — |
| TRELEGY ELLIPTA |
|
$88 | 11 | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
42 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Critical Care Medicine in Nevada
Karan Gupta
Critical Care Medicine · Las Vegas, NV
Joaquim Tavares
Critical Care Medicine · Las Vegas, NV
Farah Madhani-Lovely
Critical Care Medicine · Reno, NV
Hannah Leitch
Critical Care Medicine · Reno, NV
Ghulam Aftab
Critical Care Medicine · Las Vegas, NV
Jeffrey Bacon
Critical Care Medicine · Reno, NV
Related records
Critical Care Medicine in Nevada
Practitioners in the same specialty and state, ranked by reported value.
All Critical Care Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Nevada
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.